Liraglutide: A once-daily human glucagon-like peptide-1 analogue for type 2 diabetes mellitus

American Journal of Health-System Pharmacy

Volumn 67, Issue 16, 2010, Pages 1326-1336

  Joffe, David ^a  

^a UNIVERSITY OF FLORIDA HEALTH   (United States)

Author keywords

Antidiabetic agents; Diabetes mellitus; Dosage; Drug administration; Half life; Liraglutide; Mechanism of action; Pharmacokinetics; Toxicity

Indexed keywords

ATORVASTATIN; DIGOXIN; EXENDIN 4; GLIMEPIRIDE PLUS METFORMIN; GLUCAGON LIKE PEPTIDE 1 DERIVATIVE; GLYCOSYLATED HEMOGLOBIN; GRISEOFULVIN; INCRETIN; INSULIN DETEMIR; INSULIN GLARGINE; LIRAGLUTIDE; LISINOPRIL; METFORMIN; ORAL ANTIDIABETIC AGENT; PARACETAMOL; PLACEBO; ROSIGLITAZONE; SAXAGLIPTIN; SITAGLIPTIN; SULFONYLUREA; ANTIDIABETIC AGENT; DRUG DERIVATIVE; GLUCAGON LIKE PEPTIDE 1;

ACUTE PANCREATITIS; AREA UNDER THE CURVE; CARDIOVASCULAR RISK; CHRONIC PANCREATITIS; COMBINATION CHEMOTHERAPY; DRUG ACTIVITY; DRUG BLOOD LEVEL; DRUG COST; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG EFFECT; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG METABOLISM; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; EVENING DOSAGE; GASTROINTESTINAL SYMPTOM; GLUCOSE BLOOD LEVEL; HUMAN; HYPOGLYCEMIA; INSULIN TREATMENT; MAXIMUM PLASMA CONCENTRATION; MONOTHERAPY; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; PANCREATITIS; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; REVIEW; SIDE EFFECT; STOMACH EMPTYING; SYSTOLIC BLOOD PRESSURE; TIME TO MAXIMUM PLASMA CONCENTRATION; WEIGHT REDUCTION; DRUG ADMINISTRATION;

DIABETES MELLITUS, TYPE 2; DRUG ADMINISTRATION SCHEDULE; GLUCAGON-LIKE PEPTIDE 1; HUMANS; HYPOGLYCEMIC AGENTS;

EID: 77958045977     PISSN: 10792082     EISSN: 15352900     Source Type: Journal    
DOI: 10.2146/ajhp090230     Document Type: Review

References (81)

1. McIntyre N, Holdsworth CD, Turner DS. New interpretation of oral glucose tolerance. Lancet. 1964; 41:20-1.
2. Holst JJ. Glucagon-like peptide-1: from extract to agent. The Claude Bernard Lecture, 2005. Diabetologia. 2006; 49:253-60.
3. Drucker DJ. Enhancing incretin action for the treatment of type 2 diabetes. Diabetes Care. 2003; 26:2929-40. (Pubitemid 37205571)
4. Nauck M, Stöckmann F, Ebert R et al. Reduced incretin effect in type 2 (non-insulin-dependent) diabetes. Diabetologia. 1986; 29:46-52. (Pubitemid 16162741)
5. Holst JJ, La Salle JR. An overview of incretin hormones. J Fam Pract. 2008; 57(suppl):S4-9.
6. Nauck MA, Kleine N, Ørskov C et al. Normalization of fasting hyperglycaemia by exogenous glucagon-like peptide 1 (7-36 amide) in type 2 (non-insulin-dependent) diabetic patients. Diabetologia. 1993; 36:741-4.
7. Holst JJ. The physiology of glucagon-like peptide 1. Physiol Rev. 2007; 87:1409-39. (Pubitemid 350041474)
8. Sjöholm A. Liraglutide therapy for type 2 diabetes: overcoming unmet needs. Pharmaceuticals. 2010: 3:764-81.
9. Food and Drug Administration. Byetta (exenatide) package insert. Amylin Pharmaceuticals. www.fda.gov/cder/foi/label/2007/021773s007lbl.pdf (accessed 2008 Jul 24).
10. Food and Drug Administration. Januvia (sitagliptin phosphate) package insert. www.fda.gov/cder/foi/label/2006/021995lbl.pdf. (accessed 2008 Jul 23).
11. Onglyza (saxagliptin) package insert. Bristol-Myers Squibb Company. http://packageinserts.bms.com/pi/pi-onglyza.pdf (accessed 2009 Aug 27).
12. Food and Drug Administration. FDA approves new drug treatment for type 2 diabetes. www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm174780.htm (accessed 2010 Apr 20).
13. Victoza (liraglutide [rDNA origin] injection) package insert. Princeton, NJ: Novo Nordisk A/S; 2010.
14. Knudsen LB, Nielsen PF, Huusfeldt PO et al. Potent derivatives of glucagon-like peptide-1 with pharmacokinetic properties suitable for once daily administration. J Med Chem. 2000; 43:1664-9. (Pubitemid 30304999)
15. Steensgaard DB, Thomsen JK, Olsen HB et al. The molecular basis for the delayed absorption of the once-daily human GLP-1 analogue, liraglutide. Diabetes. 2008; 57(suppl 1):A164. Abstract.
16. Agersø H, Jensen LB, Elbrønd B et al. The pharmacokinetics, pharmacodynamics, safety and tolerability of NN2211, a new long-acting GLP-1 derivative, in healthy men. Diabetologia. 2002; 45:195-202. (Pubitemid 34208381)
17. Elbrønd B, Jakobsen G, Larsen S et al. Pharmacokinetics, pharmacodynamics, safety, and tolerability of a single-dose of NN2211, a long-acting glucagon-like peptide 1 derivative, in healthy male subjects. Diabetes Care. 2002; 25:1398-1404. (Pubitemid 41071152)
18. Degn KB, Juhl CB, Sturis J et al. One week's treatment with the long-acting glucagon-like peptide 1 derivative liraglutide (NN2211) markedly improves 24-h glycemia and alpha- and beta-cell function and reduces endogenous glucose release in patients with type 2 diabetes. Diabetes. 2004; 53:1187-94. (Pubitemid 38569002)
19. Damholt B, Golor G, Wierich W et al. An open-label, parallel group study investigating the effects of age and gender on the pharmacokinetics of the once-daily glucagon-like peptide-1 analogue liraglutide. J Clin Pharmacol. 2006; 46:635-41.
20. Kageyama S, Hirao K, Shimizu A et al. Tolerability, pharmacokinetics, and pharmacodynamics of liraglutide, long-acting human GLP-1 analogue - phase I studies in Japanese healthy subjects and subjects with type 2 diabetes. Endocrinol Diabetol. 2007; 24:95-104.
21. Seino Y, Rasmussen MF, Zdravkovic M et al. Dose-dependent improvement in glycemia with once-daily liraglutide without hypoglycemia or weight gain: a double-blind, randomized, controlled trial in Japanese patients with type 2 diabetes. Diabetes Res Clin Pract. 2008; 81:161-8.
22. Flint A, Nazzal K, Jagielski P et al. Influence of hepatic impairment on pharmacokinetics of the long-acting human GLP-1 analogue liraglutide. Diabetes. 2007; 56(suppl):A145:0545-P. Abstract.
23. Jacobsen LV, Hindsberger C, Robson R et al. Effect of renal impairment on the pharmacokinetics of the GLP-1 analogue liraglutide. Br J Clin Pharmacol. 2009; 68:898-905.
24. Bjornsdottir I, Olsen A, Larsen U et al. Metabolism and excretion of the oncedaily human GLP-1 analogue liraglutide in healthy subjects and its in vitro degradation by dipeptidyl peptidase IV and neutral endopeptidase. Diabetologia. 2008; 51(suppl):S356. Abstract.
25. Copley K, McCowen K, Hiles R et al. Investigation of exenatide elimination and its in vivo and in vitro degradation. Curr Drug Metab. 2006; 7:367-74.
26. Bergman AJ, Cote J, Yi B et al. Effect of renal insufficiency on the pharmacokinetics of sitagliptin, a selective dipeptidylpeptidase- 4 inhibitor. Diabetes Care. 2007; 30:1862-4. (Pubitemid 47036366)
27. Zdravkovic M, Hale P, Le Thi TD et al. Overview of the design of the phase 3 studies for the long-acting human GLP 1 analogue liraglutide: Liraglutide Effect and Action in Diabetes (LEAD). Diabetes. 2007; 56(suppl):abstract 2251-PO. Abstract.
28. Malm-Erjefält M, Ekblom M, Brønsted L et al. A randomised, double-blind, cross-over trial investigating the effect of liraglutide on the absorption pharmacokinetics of concomitantly administered oral drugs in healthy subjects. Diabetes. 2008; 57(suppl 1):P434. Abstract.
29. Kapitza C, Flint A, Spitzer H et al. The effect of three different injection sites on the pharmacokinetics of the once-daily human GLP-1 analogue liraglutide. Diabetes. 2008; 57(suppl 1):A593. Abstract.
30. Lennernäs H, Abrahamsson B. The use of biopharmaceutic classification of drugs in drug discovery and development: current status and future extension. J Pharm Pharmacol. 2005; 57:273-85. (Pubitemid 40326200)
31. Veterans Affairs Pharmacy Benefits Management Services. Liraglutide (Victoza) drug monograph. www.pbm.va.gov (accessed 2010 Jun 28).
32. Jacobsen LV, Brønsted L, Vouis L et al. A randomized, double-blind, cross-over trial investigating the effect of liraglutide on the absorption of an oral contraceptive drug. Diabetes. 2008; 57(suppl 1): P2047. Abstract.
33. Vilsbøll T, Brock B, Perrild H et al. Liraglutide, a once-daily human GLP-1 analogue, improves pancreatic B-cell function and arginine-stimulated insulin secretion during hyperglycaemia in patients with type 2 diabetes mellitus. Diabet Med. 2008; 25:15-6.
34. Vilsbøll T, Zdravkovic M, Le-Thi T et al. Liraglutide, a long-acting human glucagon-like peptide-1 analog, given as monotherapy significantly improves glycemic control and lowers body weight without risk of hypoglycemia in patients with type 2 diabetes. Diabetes Care. 2007; 30:1608-10. (Pubitemid 46871185)
35. Nauck MA, Hompesch M, Filipczak R et al. Five weeks of treatment with the GLP-1 analogue liraglutide improves glycaemic control and lowers body weight in subjects with type 2 diabetes. Exp Clin Endocrinol Diabetes. 2006; 114:417-23. (Pubitemid 44620484)
36. Marre M, Shaw J, Brandle M et al. Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with type 2 diabetes (LEAD-1 SU). Diabet Med. 2009; 26:268-78.
37. Nauck MA, Frid A, Hermansen K et al. Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin in type 2 diabetes mellitus: the LEAD Liraglutide Effect and Action in Diabetes-2 study. Diabetes Care. 2009; 32:84-90.
38. Garber A, Henry R, Ratner R et al. Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): randomised, 52-week, phase III, double-blind, parallel-treatment trial. Lancet. 2009; 373:473-81.
39. Zinman B, Gerich J, Buse JB et al. (LEAD 4). Efficacy and safety of the human GLP-1 analog liraglutide in combination with metformin and TZD in patients with type 2 diabetes mellitus (LEAD-4 Met+TZD). Diabetes Care. 2009; 32: 1224-30.
40. Russell-Jones D, Vaag A, Schmitz O et al. Liraglutide vs insulin glargine and placebo in combination with metformin and sulphonylurea therapy in type 2 diabetes mellitus: a randomised controlled trial (LEAD-5 met+SU). Diabetologia. 2009; 52:2046-55.
41. Buse JB, Rosenstock J, Sesti G et al. A study of two glucagon-like peptide-1 receptor agonists for the treatment of type 2 diabetes: liraglutide once daily compared with exenatide twice daily in a randomised, 26-week, open-label trial (LEAD-6). Lancet. 2009; 374:39-47.
42. Riedel AA, Heien H, Wogen J et al. Loss of glycemic control in patients with type 2 diabetes mellitus who were receiving initial metformin, sulfonylurea, or thiazolidinedione monotherapy. Pharmacotherapy. 2007; 27:1102-10. (Pubitemid 47173656)
43. Monnier L, Lapinski H, Colette C. Contributions of fasting and postprandial plasma glucose increments to the overall diurnal hyperglycemia of type 2 diabetic patients: variations with increasing levels of HbA(1c). Diabetes Care. 2003; 26:881-5. (Pubitemid 36929359)
44. Zinman B, Colagiuri S, Madsbad S et al. The human GLP-1 analog, liraglutide, improves BMI and waist circumference in patients with type 2 diabetes: metaanalysis of six phase 3 trials. Diabetes. 2010; 59(suppl 1):A495. Abstract.
45. Jendle J, Nauck MA, Matthews DR et al. Weight loss with liraglutide, a oncedaily human glucagon-like peptide-1 analogue for type 2 diabetes treatment as monotherapy or added to metformin, is primarily as a result of a reduction in fat tissue. Diabetes. 2009; 11:1163-72.
46. Janiszewski PM, Kuk JL, Ross R. Is the reduction of lower-body subcutaneous adipose tissue associated with elevations in risk factors for diabetes and cardiovascular disease? Diabetologia. 2008; 51:1475-82.
47. Stratton IM, Adler AI, Neil HA et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ. 2000; 321:405-12. (Pubitemid 30609442)
48. Doyle ME, Egan JM. Mechanisms of action of glucagon-like peptide 1 in the pancreas. Pharmacol Ther. 2007; 113:546-93. (Pubitemid 46365961)
49. Mari A, Degn K, Brock B et al. Effects of the long-acting human glucagon-like peptide-1 analog liraglutide on beta-cell function in normal living conditions. Diabetes Care. 2007; 30:2032-3. (Pubitemid 47219415)
50. Matthews DR, Marre M, Le Thi TD et al. Liraglutide, a human GLP-1 analogue, significantly improves beta-cell function in subjects with type 2 diabetes. Diabetologia. 2008; 51(suppl 1):abstract 892. Abstract.
51. Grundy SM, Benjamin IJ, Burke GL et al. Diabetes and cardiovascular disease: a statement for healthcare professionals from the American Heart Association. Circulation. 1999; 100:1134-46. [Erratum, Circulation. 2000; 101:1629-31.]
52. Patel A; ADVANCE Collaborative Group, MacMahon S, Chalmers J et al. Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial. Lancet. 2007; 370:829-40.
53. Colagiuri S, Frid A, Zdravkovic M et al. Liraglutide, a human GLP-1 analogue, reduces systolic blood pressure in subjects with type 2 diabetes. Diabetologia. 2008; 51(suppl 1):S360. Abstract.
54. Heran BS, Wong MM, Heran IK et al. Blood pressure lowering efficacy of angiotensin converting enzyme (ACE) inhibitors for primary hypertension. Cochrane Database Syst Rev. 2008; 4:CD003823.
55. Heran BS, Wong MM, Heran IK et al. Blood pressure lowering efficacy of angiotensin receptor blockers for primary hypertension. Cochrane Database Syst Rev. 2008; 4:CD003822.
56. Korytkowski M. When oral agents fail: practical barriers to starting insulin. Int J Obes Relat Metab Disord. 2002; 26(suppl 3):S18-24.
57. De Heer J, Holst JJ. Sulphonylurea compounds uncouple the glucose dependence of the insulinotropic effect of glucagonlike peptide-1. Diabetes. 2007; 56:438-43.
58. Irie S, Matsumura Y, Zdravkovic M et al. Tolerability, pharmacokinetics and pharmacodynamics of the once-daily human GLP-1 analog liraglutide in Japanese healthy subjects: a randomized, doubleblind, placebo-controlled dose-escalation study. Int J Clin Pharmacol Ther. 2008; 46:273-9. (Pubitemid 351890729)
59. Food and Drug Administration. Safety information for healthcare professionals: exenatide (marketed as Byetta). www.fda.gov/Drugs/DrugSafety/ PostmarketDrugSafetyInformationforPatientsandProviders/ucm124713.htm (accessed 2010 Jun 23).
60. Food and Drug Administration. Safety information for healthcare professionals: sitagliptin (marketed as Januvia and Janumet). www.fda.gov/Drugs/DrugSafety/ PostmarketDrugSafetyInformationforPatientsandProviders/ucm183768.htm (accessed 2009 Oct 29).
61. Novo Nordisk A/S. Victoza (liraglutide) package insert. www.novonordisk.com/diabetes/hcp/pharmaceuticals/victoza (accessed 2010 Jun 23).
62. Noel R, Braun D, Patterson R et al. Increased risk of acute pancreatitis observed in patients with type 2 diabetes. Paper presented at 24th International Conference on Pharmacoepidemiology and Therapeutic Risk Management. Copenhagen, Denmark; 2008 Aug 17.
63. Tandon N, John M, Sharma SK et al. A clinician's perspective on liraglutide in clinical practice. J Assoc Physicians India. 2010; 58:29-30.
64. Korytkowski M, Bell D, Jacobsen C et al. A multicenter, randomized, open-label, comparative, two-period crossover trial of preference, efficacy and safety profiles of a prefilled, disposable pen and conventional vial/syringe for insulin injection in patients with type 1 or 2 diabetes mellitus. Clin Ther. 2003; 25:2836-48. (Pubitemid 37510593)
65. Korytkowski M, Niskanen L, Asakura T. FlexPen: addressing issues of confidence and convenience in insulin delivery. Clin Ther. 2005; 27(suppl B):S89-100.
66. Buse J, Sesti G, Schmidt WE et al. Switching from twice-daily exenatide to once-daily liraglutide improves glycemic control in T2D on oral agents. Diabetes. 2009; 58(suppl 1):A159. Abstract.
67. Madsbad S, Krarup T, Deacon CF et al. Glucagon-like peptide receptor agonists and dipeptidyl peptidase-4 inhibitors in the treatment of diabetes: a review of clinical trials. Curr Opin Clin Nutr Metab Care. 2008; 11:491-9.
68. Amori RE, Lau J, Pittas AG. Efficacy and safety of incretin therapy in type 2 diabetes: systematic review and meta-analysis. JAMA. 2007; 298:194-206. (Pubitemid 47057766)
69. Raun K, von Voss P, Gotfredsen CF et al. Liraglutide, a long-acting glucagon-like peptide-1 analog, reduces body weight and food intake in obese candy-fed rats, whereas a dipeptidyl peptidase-IV inhibitor, vildagliptin, does not. Diabetes. 2007; 56:8-15.
70. Buse J, Henry RR, Jan J et al. Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes. Diabetes Care. 2004; 27:2628-35. (Pubitemid 39441462)
71. Food and Drug Administration. Byetta (exenatide): renal failure. www.fda.gov/Safety/MedWatch/SafetyInformation/ SafetyAlertsforHumanMedicalProducts/ucm188703.htm (accessed 2009 Nov 2).
72. Jacobsen L, Hindsberger C, Robson R et al. Effect of renal impairment on the pharmacokinetics of the GLP-1 analogue liraglutide. Br J Clin Pharmacol. 2009; 68:898-905.
73. Buse JB, Drucker DJ, Taylor KL et al. DURATION-1: exenatide once weekly produces sustained glycemic control and weight loss over 52 weeks. Diabetes Care. 2010; 33:1255-61.
74. Novo Nordisk. R&D pipeline, 2010. www.novonordisk.com/press/rd- pipeline/rd-pipeline.asp?showid=7 (accessed 2010 Jun 28).
75. DeFronzo R, Ratner RE, Han J et al. Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes. Diabetes Care. 2005; 28:1092-1100. (Pubitemid 40616618)
76. Kendall DM, Riddle MC, Rosenstock J et al. Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea. Diabetes Care. 2005; 28:1083-91. (Pubitemid 40616617)
77. Nathan DM, Buse JB, Davidson MB et al. Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy. Diabetes Care. 2008; 31:1-11.
78. Rodbard H, Jellinger P, Davidson J et al. Statement by an American Association of Clinical Endocrinologists/American College of Endocrinology consensus panel on type 2 diabetes mellitus: an algorithm for glycemic control. Endocr Pract. 2009; 15:541-59.
79. Knop FK, Holst JJ, Vilsbøll T. Replacing SUs with incretin-based therapies for type 2 diabetes mellitus: challenges and feasibility. IDrugs. 2008; 11:497-501. (Pubitemid 351950862)
80. Sullivan S, Alfonso-Cristancho R, Conner C et al. Long-term outcomes in patients with type 2 diabetes receiving glimepiride combined with liraglutide or rosiglitazone. Cardiovasc Diabetol. 2009; 8:12.
81. Liebl A. Myths, realities and practicalities in the initiation of intensification of insulin therapy in type 2 diabetes. Eur Endocrinol. 2009; 4:27-30.